Helion raises $425 million from SoftBank's venture arm, hits $5.4 billion valuation
By Stephen Nellis
(Reuters) - Helion, a startup working to generate electricity from nuclear fusion, on Tuesday said it has raised $425 million in venture funding from a group of investors including SoftBank Group's Vision Fund 2.
The Everett, Washington-based Helion said the funding will help it speed up the development of its next generation fusion reactor design, which aims to tap into the same reactions that power the sun to make carbon-free electricity without long-lasting radioactive waste. The company has an agreement with Microsoft to begin providing power in 2028.
Helion is among the dozens of public and private groups looking to crack the key challenge of fusion: how to get more electricity out of the nuclear reaction than it takes to create and contain it.
Rather than use fusion to heat water into steam that would turn a power turbine, Helion uses powerful magnets and electronic components such as capacitors and thyristors - which allow power to flow in only one direction - to capture fusion energy directly through electromagnetic induction.
In an interview, Helion Chief Executive David Kirtley said the 6,000 massive capacitors and 50,000 thyristors needed for the firm's current machine were secured from outside suppliers and often had to be adapted from industrial uses.
Helion, which employs 450 people, plans to start manufacturing its own capacitors, which will help add about 100 jobs.
"It took years to get all them in-house from external suppliers, and we need to turn up those rates," Kirtley said. "That's the goal - to do that all in house in the United States."
Kirtley said the funding will also help Helion design and prototype custom thyristors for the next machine.
Other investors in the funding round include Lightspeed Venture Partners and a major university endowment fund that Kirtley declined to name.
Also joining the round were Helion's existing investors: OpenAI CEO Sam Altman; Mithril Capital, which was co-founded by Peter Thiel; Capricorn Investment Group, Facebook co-founder Dustin Moskovitz; and steel producer Nucor.
(This story has been corrected to clarify that Helion's funding round includes significant participation from new and existing investors in paragraph 1)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
36 minutes ago
- Wall Street Journal
GOP Senators' Competing Demands Risk Pulling Trump Megabill Apart
WASHINGTON—Senate Majority Leader John Thune (R., S.D.) is trying to release this week a revised version of President Trump's 'big, beautiful bill.' But as he races to pass the legislation ahead of Republicans' self-imposed July 4 deadline, he has got about as many problems as there are GOP senators, with lawmakers battling over the additional borrowing and spending cuts that will be used to finance tax relief, plus spending on the border and military.


Bloomberg
42 minutes ago
- Bloomberg
Gold Steadies After Two-Day Loss Ahead of US-China Trade Talks
Gold was steady — after losing almost 2% over the previous two sessions — as another round of US-China trade talks offered hope trade tensions between the two largest economies can be eased. Bullion traded above $3,306 an ounce, after dropping Friday as better-than-expected US jobs data reduced some concerns about the nation's economic downturn. Top trade negotiators from Washington and Beijing are set to hold fresh talks in London on Monday, with China's dominance in rare earths production a major focus.
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data